Prostate cancer market to reach $596.22m by 2028
Thanks to a steady rise in clinical trials involving an innovator drug.
The prostate cancer market is projected to increase by 25% from $475.8m to $596.22m by 2028, said GlobalData.
The sector’s expansion is attributed to a steady rise in clinical trials involving an innovator drug and a growing portfolio of approved therapies over the past decade.
While there has been a slight dip in innovator trials and therapies in 2024, the report noted that the year is ongoing, leaving room for figures to recover and potentially surpass previous levels.
Meanwhile, diagnosed prevalent cases are forecasted to increase by 6.3% within the same period.